NCT05172037Unknown3 期
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients With Mild COVID-19
适应症
试验速览
- 阶段
- 3 期
- 发起方
- Genova Inc.
- 入组人数
- 222
- 试验地点
- 1
- 主要终点
- Rate of severe conditions with Score 3 or more serious on a seven-point ordinal scale from the start date of investigational drug administration (Day 1) to Day 28.
研究概览
简要总结
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients with Mild COVID-19
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent has been obtained from the participants with an age of over 20 years at the time of signing the informed consent.
- •SARS-CoV-2 infection is diagnosed by RT-PCR within 72 hours before starting drug administration.
- •Less than six days from onset of COVID-19-related symptoms below to starting the administration of the investigational drug with at least one of the following symptoms observed at the time of enrollment : fever (37.5C or higher), respiratory symptoms (cough, shortness of breath, sore throat, runny nose, etc.), headache, myalgia, malaise, abdominal pain, diarrhea, nausea/vomiting, dysosmia, dysgeusia, or other COVID-19 symptoms defined by investigators or coinvestigators investigators.
- •Oxygen saturation (SpO2) measured by pulse oximeter is more than 95%.
- •Require no supplemental oxygen.
- •Women (less than 12 months after the last menstrual period) who have a negative pregnancy test (urine hCG qualification) and agree to use highly effective contraceptive methods (taking oral contraceptives or use of condom by male partner) during the study period. Investigators or coinvestigators investigators will provide guidance on contraceptive methods.
- •Women who are not breast-feeding.
排除标准
- •History of hypersensitivity to interferon or JH509 or any excipients of interferon or JH
- •Have received antiviral treatments and drugs expected to have antiviral effects (Favipiravir, Remdesivir, Interferon, Nafamostat mesilate, and Basiliximab/Imdevimab, including drugs that are being newly developed and that have been approved) in the past or having had it considered necessary to receive these treatments during the study period.
- •Having had it considered necessary to receive treatments, such as drugs containing corticosteroids (excluding topical drugs), antimicrobial agents, and inhalants other than the investigational drug during the study period.
- •Taking "Shosaikoto," an herbal medicine.
- •Neuropsychiatric disorder and autoimmune disorder.
- •CTCAE Grade 3 or higher liver dysfunction (ALT/AST > 5ULN) or renal dysfunction (eGFR < 30 mL/min/1.73 m2).
- •Active infections or other medical conditions that contraindicate inhalation therapy.
- •Having the complication of malignant tumor or a history of malignant tumor within 1 year before consent acquisition.
- •Inappropriate for inclusion in the clinical trial as determined by investigators or coinvestigators investigators.
结局指标
主要结局
Rate of severe conditions with Score 3 or more serious on a seven-point ordinal scale from the start date of investigational drug administration (Day 1) to Day 28.
时间窗: 28 day
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma GangrenosumPyoderma GangrenosumNCT05964413InflaRx GmbH54
已完成
3 期
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal WomenHypoactive Sexual Desire DisorderNCT00612742BioSante Pharmaceuticals3,656
终止
3 期
A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 SubjectsCovid19NCT05009732Suzhou Kintor Pharmaceutical Inc,139
已完成
3 期
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyNarcolepsyCataplexyExcessive Daytime SleepinessNCT05059223Axsome Therapeutics, Inc.90
已完成
3 期
A Study of IBI306 in Participants With HypercholesterolemiaHypercholesterolemiaNCT04709536Innovent Biologics (Suzhou) Co. Ltd.306